BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 14521406)

  • 1. Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA.
    Raichurkar AV; Kulkarni VM
    J Med Chem; 2003 Oct; 46(21):4419-27. PubMed ID: 14521406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2006 Nov; 41(11):1279-92. PubMed ID: 16919851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
    Juvale DC; Kulkarni VV; Deokar HS; Wagh NK; Padhye SB; Kulkarni VM
    Org Biomol Chem; 2006 Aug; 4(15):2858-68. PubMed ID: 16855733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR studies on malonyl coenzyme A decarboxylase inhibitors.
    Patel MR; Talele TT
    Bioorg Med Chem; 2007 Jul; 15(13):4470-81. PubMed ID: 17482825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
    Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
    J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
    Puntambekar D; Giridhar R; Yadav MR
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
    Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
    J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.
    Trossini GH; Guido RV; Oliva G; Ferreira EI; Andricopulo AD
    J Mol Graph Model; 2009 Aug; 28(1):3-11. PubMed ID: 19376735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
    Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
    Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods.
    Zhu YQ; Pei JF; Liu ZM; Lai LH; Cui JR; Li RT
    Bioorg Med Chem; 2006 Mar; 14(5):1483-96. PubMed ID: 16256351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
    Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
    Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents.
    Murugesan V; Prabhakar YS; Katti SB
    J Mol Graph Model; 2009 Feb; 27(6):735-43. PubMed ID: 19117780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
    Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
    Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
    Puntambekar DS; Giridhar R; Yadav MR
    Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors.
    Chaudhaery SS; Roy KK; Saxena AK
    J Chem Inf Model; 2009 Jun; 49(6):1590-601. PubMed ID: 19441865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors.
    Hu X; Stebbins CE
    Bioorg Med Chem; 2005 Feb; 13(4):1101-9. PubMed ID: 15670918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
    Bhongade BA; Gadad AK
    Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.